Roivant Sciences climbs to $7 billion valuation

Roivant Sciences climbs to $7 billion valuation

Roivant Sciences has raised $200 million in a new funding round that makes it one of the most highly valued private firms in the history of the biotechnology industry at $7 billion, according to the company. Previous backers, including SoftBank's Vision Fund took part in the new financing, as did new investors NovaQuest Capital Management and RTW Investments, Roivant said Tuesday.

from Biotech News